Patients with high-risk features can benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT), but 20% of patients with AML with RUNX1::RUNX1T1 relapse after that and the dynamics of the transcript levels can predict relapse in these patients [12, 13] . This evidence concerns the gene RUNX1 and acute myeloid leukemia.